Project Eleven | $20,000,000 | (Jan 16, 2026)
CYB3R OPERATIONS | $5,400,000 | (Jan 16, 2026)
Quadric | $30,000,000 | (Jan 16, 2026)
Certified by Founder
Lodge
Deverra Therapeutics
start up
United States
- Seattle
- 20/09/2023
- Unknown
- $2,400,000
Deverra Therapeutics is a clinical stage biotechnology company dedicated to the development of allogeneic, off-the-shelf cellular immunotherapies for on-demand treatment of patients with cancer and infectious diseases. The company has an exclusive license to a proprietary stem cell expansion and directed-differentiation platform from the Fred Hutchinson Cancer Research Center based on more than 20 years of federally funded research and data from 5 clinical trials. This platform can be used to generate a range of unmodified and modified immune cells to treat patients with cancer and infectious diseases.
- Industry Biotechnology
- Website https://www.deverratx.com/
- LinkedIn https://www.linkedin.com/company/deverra-therapeutics/about/
GovDash | $30,000,000 | (Jan 16, 2026)
RouteSense | $2,000,000 | (Jan 16, 2026)
Vista AI | $29,500,000 | (Jan 16, 2026)
depthfirst | $40,000,000 | (Jan 16, 2026)
Slips | $3,500,000 | (Jan 16, 2026)
FOVC | $2,000,000 | (Jan 16, 2026)
VoiceRun | $5,500,000 | (Jan 16, 2026)
Emversity | $30,000,000 | (Jan 16, 2026)
Ammobia | $7,500,000 | (Jan 16, 2026)
Pinch AI | $5,000,000 | (Jan 16, 2026)